Pulse Biosciences Inc

For the period ended Dec 31, 2023. Filed Mar 28, 2024.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2023 · Filed Mar 28, 2024

PLSE$55.12-5.2%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Consolidated Statements of Stockholders’ (Deficit) Equity

Consolidated Statements of Stockholders’** Equity (Deficit)**

(in thousands, except per share amount)

Additional · Accumulated Other · Total
Common Stock · Paid-in · Comprehensive · Accumulated · Stockholders’
	Shares	Amount	Capital	Income (Loss)	Deficit	Equity (Deficit)
Balance, December 31, 2021	29,716	29	271,861	—	(236,200)	35,690
Issuance of shares in Rights Offering, net of issuance costs of $136	7,317	7	14,857	—	—	14,864
Issuance of shares under employee stock purchase plan	188	1	485	—	—	486
Issuance of shares upon exercise of warrants	14	—	26	—	—	26
Stock-based compensation expense	—	—	5,191	—	—	5,191
Net loss	—	—	—	—	(58,505)	(58,505)
Balance, December 31, 2022	37,235	$37	$292,420	$—	$(294,705)	$(2,248)
Issuance of common stock as part of debt extinguishment, net of issuance costs of $6	10,023	10	65,233	—	—	65,243
Issuance of shares upon exercise of warrants, net of issuance costs of $9	7,238	7	14,821	—	—	14,828
Issuance of shares under employee stock purchase plan	347	1	394	—	—	395
Issuance of common stock upon exercise of stock options	301	—	1,171	—	—	1,171
Stock-based compensation expense	—	—	7,181	—	—	7,181
Net loss	—	—	—	—	(42,210)	(42,210)
Balance, December 31, 2023	55,144	$55	$381,220	$—	$(336,915)	$44,360

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.